Vitiligo, Generalized
9
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.
Vitiligo Treatment by Targeting TYK2 Mediated Responses
Vitiligo, New Treatment and Serum s100B
Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
Autologous Cellular Graft in Surgical Treatment of Vitiligo
Phototherapy Combination With Topicals in Vitiligo
Catecholamines Level in Vitiligo Patients Before and After Excimer Light